Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in CHF (TTM)60.50bn
  • Net income in CHF8.28bn
  • Incorporated1966
  • Employees103.25k
  • Location
    Roche Holding AGGrenzacherstrasse 124BASEL 4002SwitzerlandCHE
  • Phone+41 616881111
  • Websitehttps://www.roche.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gilead Sciences Inc22.89bn4.75bn108.64bn17.60k23.197.1215.614.754.734.7322.7915.390.50983.456.351,632,671.0010.585.2613.636.3878.2978.4720.7612.541.237.800.5667108.476.045.08-91.53-38.34-8.714.10
Pfizer Inc49.75bn6.27bn116.16bn81.00k18.611.619.862.331.381.3810.9515.890.29111.465.47771,148.103.687.454.499.4374.5769.1012.6420.370.960412.260.406664.226.849.10275.82-5.272.323.13
Amgen Inc27.18bn4.73bn126.47bn28.00k26.9525.5813.764.6510.9610.9663.0511.540.37431.594.581,218,786.006.518.438.5010.6664.0772.8117.3921.900.8787.060.902471.3718.577.43-39.11-12.2112.149.18
Merck & Co Inc50.92bn13.89bn166.73bn75.00k12.134.349.473.276.876.8725.1919.210.57862.315.77852,293.3015.799.5220.4612.6477.0773.4727.3017.871.1623.900.418672.966.7410.404,589.5924.64-0.58856.66
AstraZeneca plc43.80bn6.19bn175.22bn94.30k28.505.3617.084.003.693.6926.0719.610.52731.734.52431,926.507.464.3210.355.9582.3680.2214.159.390.695410.420.4348107.6818.0317.2718.1439.4313.271.20
Novo Nordisk A/S37.83bn13.05bn185.69bn77.41k18.6914.0612.514.9123.4823.4868.0331.210.76931.244.793,972,910.0026.5527.7254.1555.7484.3384.2534.5134.120.557147.340.461550.1125.0318.9420.6820.9935.5022.25
Novartis AG42.36bn10.24bn203.15bn75.88k18.916.1713.484.805.095.0921.0215.600.54752.246.47558,203.1013.249.8019.3113.0875.6673.7624.1824.420.609717.410.447866.4210.851.2439.3710.8311.064.83
Roche Holding AG60.50bn8.28bn209.63bn103.25k24.886.4316.623.4710.3210.3275.4339.940.62932.065.42585,913.709.5614.4813.9122.5173.9171.9715.1921.431.2015.670.489464.023.03-0.318-28.01-9.320.45741.51
AbbVie Inc45.70bn3.31bn270.78bn55.00k82.06239.3826.955.932.352.3532.390.8040.40253.834.701,043,036.002.955.444.067.0970.6968.897.3313.730.63597.800.9795134.963.7111.11-12.07-11.5812.037.69
Johnson & Johnson71.16bn17.37bn300.71bn138.10k17.444.8312.974.238.998.9936.8332.470.48862.355.77646,857.4011.938.6316.7811.7368.3468.7024.4118.291.03--0.400874.744.301.605.55-1.434.815.54
Data as of Jul 11 2025. Currency figures normalised to Roche Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

17.99%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management Switzerland AGas of 01 Jul 202526.71m3.80%
The Vanguard Group, Inc.as of 02 Jul 202526.24m3.73%
Norges Bank Investment Managementas of 31 Dec 202418.71m2.66%
BlackRock Fund Advisorsas of 03 Jul 202514.62m2.08%
Z�rcher Kantonalbank (Investment Management)as of 30 May 202510.38m1.48%
Geode Capital Management LLCas of 04 Jul 20258.20m1.17%
BlackRock Advisors (UK) Ltd.as of 04 Jul 20256.97m0.99%
BlackRock Asset Management Deutschland AGas of 04 Jul 20255.67m0.81%
Pictet Asset Management SAas of 31 May 20254.71m0.67%
MFS International (UK) Ltd.as of 31 May 20254.20m0.60%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.